Top of the morning to you, and a fine one, it is. Despite the rising humidity, we are enjoying a shiny sun and hints of a cool breeze wafting about the Pharmalot campus, where the shortest person is now sleeping in, since the local summer job has come to an end. Our own work, however, proceeds apace. And this calls for firing up the coffee kettle and quaffing a few cups of stimulation. Feel free to join us or, if you prefer, grab a mug of water before you tackle your own to-do list. Hope all goes well on your journey today and, as always, do keep in touch …

In a biting letter to Cigna (CI) shareholders, Carl Icahn called the proposed $54 billion acquisition of Express Scripts (ESRX) “completely ridiculous” and argued the insurer is “dramatically overpaying for a highly challenged (company) that is facing existential risks on several fronts.” He cited “regulatory risk” caused by “opposition to the highly flawed rebate system,” which will hurt Express Scripts profits, and pointed to “competitive risk from Amazon (AMZN), arguably the strongest competitor in the world, will be an existential threat to PBMs like Express Scripts, possibly challenging their very existence.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy